Abstract: Lung volume reduction surgery (LVRS) has been shown to improve lung function and exercise tolerance in patients with severe emphysema. Some predictors of poor outcome have been described but the role of alpha 1 -antitrypsin (α 1 -AT) defi ciency is still not well known. The aim of this study was to analyze the results of unilateral LVRS in our center according to the α 1 -AT status. The results of LVRS in 17 defi cient patients and 35 nondefi cient patients were analyzed at 3-6 months and 1 year after surgery. Compared with baseline, a signifi cant improvement of FEV 1 , partial pressure in arterial blood (PaO 2 ), dyspnea score and walking distance was observed in the two groups at 3-6 months after surgery and the studied parameters remained signifi cantly improved at 1 year in the nondefi cient group. By contrast, PaO 2 and walking distance returned towards baseline in the defi cient group at 1 year whereas improvement of FEV 1 and dyspnea score was persistent. Mean values of FEV 1 at baseline, 3-6 months, and 1 year were 22 ± 6%, 29 ± 11%, and 26 ± 9% and 28 ± 12%, 38 ± 17%, and 40 ± 17% predicted in the defi cient group and in the non-defi cient group, respectively. In conclusion, the functional benefi t is short-lasting in α 1 -AT defi cient patients after unilateral LVRS.
Introduction
Emphysema is a progressive, debilitating disease associated with a high rate of morbidity. LVRS has been shown to be effective in providing short-term, medium-term, and long-term benefi t in patients with emphysema Flaherty and Martinez 2000; Yusen et al 2003; Weder 2003) . The NETT study, a large, randomized, controlled trial comparing LVRS and medical therapy, has also shown that LVRS is able to provide a better 24-month functional outcome than medical treatment alone but without difference in mortality rate (NETT 2003) . Moreover, this study was able to defi ne a group of patients with high risk of mortality after LVRS (NETT 2001) . While several teams have identifi ed predictive factors of good functional results (Wang et al 1997; NETT 2003; Ingenito et al 1998 Ingenito et al , 2001 Thurnheer et al 1999) , the infl uence of α 1 -AT defi ciency on functional results remains debated. The studies which have focused on the results of LVRS in patients with α 1 -AT defi ciency have yielded controversial results Cassina et al 1998; Gelb et al 1999; Rischer et al 1999) . Taking these results into account, the ATS-ERS statement on the standards for the diagnosis and management of individuals with α 1 -AT defi ciency has recently concluded that LVRS offers only short-term benefi ts for most defi cient patients and that LVRS should not be recommended in these patients pending additional studies (ATS-ERS 2003) .
In 1994, a prospective program of LVRS was started at our center. The α 1 -AT defi cient patients were not excluded a priori from the program thus giving us 
Materials and methods
Patients who met the predefi ned selection criteria (see below), and who accepted the risks and the uncertainties of LVRS underwent either bilateral or unilateral LVRS which were performed by the same surgeon (GL). After surgery, the patients were asked to visit our center at regular intervals in order to assess their functional results. Between January 1994 and December 2001, 66 patients underwent unilateral LVRS whereas 17 patients had bilateral surgery.
In order to homogenize the data, we selected only the patients who underwent unilateral LVRS. Among the 66 patients who had unilateral LVRS, 13 patients in whom the α 1 -AT status was unknown were excluded from this study. One patient who underwent LVRS after lung transplantation was also excluded. Thus, 52 patients in whom the α 1 -AT status was known form the basis of the study. α 1 -AT defi ciency was found in 17 patients (defi cient group) whereas 35 patients had no defi ciency (nondefi cient group). α 1 -AT defi ciency was defi ned as PiZZ phenotype or α 1 -AT serum level below 50 mg/ml. The fi les of these patients were analyzed and several items were retrieved: preoperative characteristics, perioperative and overall mortality, post-operative morbidity. The functional results of LVRS in the two groups were studied at 3-6 months and at 1 year after surgery.
Selection criteria
To be considered for LVRS, the patients had to meet the following selection criteria: physiologic evidence of severe airfl ow obstruction (FEV 1 < 40% predicted), hyperinfl ation (defi ned as a TLC value above predicted without threshold of TLC), severe dyspnea defi ned as a Fletcher dyspnea score > 2, and CT scan evidence of advanced emphysema with some degree of heterogeneity in the distribution of emphysema.
The exclusion criteria for LVRS were as follows: age > 75 years, presence of giant bulla defi ned as a bulla > 1/3 of hemithorax on the CT scan, severe left ventricular dysfunction, or BMI < 18 kg.m -2 . The levels of hypercapnia and pulmonary hypertension were not considered as exclusion criteria.
Pre-and post-operative evaluation
All patients underwent baseline pulmonary function tests, CT scan of the thorax, and lung ventilation-perfusion scan. Cardiac function evaluation was made using echocardiography and right heart catheterization. Coronary angiography was performed in case of symptoms. Pulmonary function tests included spirometry, and measurement of DLCO and thoracic gas volumes. TLC was measured by standardized body plethysmography (MedGraphics 1085 series Plethysmograph). Exercise capacity was assessed by the 6MWD test. Arterial blood gas analysis was made at rest on room air (AVL analyser, Radiometer, Copenhagen). Severity of pre-and post-operative dyspnea was assessed using the score described by Fletcher (1952) . Pulmonary artery pressure and cardiac index were evaluated during right heart catheterization. Pre-operative CT and ventilation-perfusion scans were used to identify target areas for lung resection. Post-operatively, all these tests were repeated between 3 and 6 months and at 1 year except for right heart catheterization which was not performed after surgery.
Surgical procedure
All patients underwent unilateral LVRS at the same center, by the same thoracic surgeon (GL). The LVRS procedure was performed in all cases via unilateral thoracotomy. The worst areas of emphysematous lung were resected by stapling guided by the results of CT and lung perfusion scan.
Statistical analysis
Baseline characteristics are reported as mean and standard deviation. Preoperative and post-operative differences between groups were compared by means of Student's t-test. In each group, comparisons between baseline values and values at 3-6 months and between baseline values and values at 1 year were made using paired Student's t-test. The comparison of the relative gain of FEV 1 at 3-6 months and 1 year from baseline between the two groups was analyzed using t-test (the variables are normally distributed). The proportion of patients with improved FEV 1 (defi ned as a gain > 150 ml) and 6MWD (defi ned as a gain > 50 m) at 3-6 months and 1 year was assessed by a χ 2 test. A p value < 0.05 was considered statistically signifi cant.
Results
Baseline characteristics of the patients are shown in Table  1 . All patients were dyspneic at rest or for mild exercise lower lobe in all the α 1 -AT defi cient patients and on the lower or the upper lobes in the nondefi cient group. Among the 35 patients in the latter group, 19 had predominant lower lobe lesions.
Mortality and morbidity
Hospital mortality was defi ned as death occurring before a patient's discharge from the hospital after LVRS. Two patients died within this period, resulting in a mortality rate of 3.8%. These patients from the nondefi cient group died at day 16 from septic shock related to peritonitis and at day 36 from bacterial pneumonia. Neither patients with PaCO 2 level > 55 mmHg or pulmonary artery hypertension > 55 mmHg died during hospital stay. If we except the patients who died in the early post-operative period, the remaining 50 patients were alive at 3-6 months and at 1 year. Thus, the 1-year mortality rate among the followed patients was 3.8%.
LVRS morbidity consisted of lower respiratory tract infection and persistent air leak. No other complication was observed in our series. The average duration of chest drainage was 9.0 ± 5 days and 9.8 ± 6 days in the nondefi cient group and in the defi cient group, respectively. The average duration of hospital stay was 24 days in the two groups.
Concerning lower respiratory tract infection, 3 of the 17 patients in the defi cient group and 4 of the 35 patients in the nondefi cient group developed nosocomial purulent bronchitis or pneumonia.
Functional results
At 3-6 months, functional data were available in all patients (except in the two who died early in the nondefi cient group) while the data were lacking at 1 year in 8 other patients (1 in the defi cient group and 7 in the nondefi cient group). While 1 of these 8 patients with nonavailable functional results at 1 year was reoperated on the controlateral side between 6 months and 1 year, the other 7 patients did not undergo their 1-year evaluation. The functional results in the two groups are shown in Table 2 and in Figures 1, 2 , and 3.
Defi cient group
Compared with baseline, a signifi cant improvement of mean FEV 1 at 3-6 months was observed in the α 1 -AT defi cient group (from 22.2 ± 6% pred to 28.9 ± 11% pred; p < 0.002). A signifi cant gain in PaO 2 and 6MWD and a signifi cant decrease in dyspnea score were also observed. At 1 year postoperative, a decline in pulmonary function values, 6MWD, and PaO 2 was noted but FEV 1 value and dyspnea score remained signifi cantly improved compared with baseline. (Fletcher dyspnea score = 4.2 ± 0.7 in the defi cient group and 3.6 ± 0.8 in the nondefi cient group; p = 0.02). We observed a severe limitation in exercise capacity in the two groups (6MWD = 237 ± 145 m and 340 ± 173 m in the defi cient group and in the nondefi cient groups, respectively; p = 0.04). The defi cient patients tended to have more severe airfl ow obstruction than nondefi cient patients (FEV 1 = 22.2 ± 6% predicted [pred] and 28 ± 12% pred in the defi cient group and in the nondefi cient group, respectively; p = 0.06). Severe hyperinfl ation was observed in the two groups (TLC = 138 ± 18% pred and RV = 278 ± 48% pred in the deficient group, TLC = 129 ± 21% pred and RV = 259 ± 71% pred in the nondefi cient group; p = 0.15 and p = 0.34, respectively). Mean PaO 2 was 62 ± 10 mmHg in the defi cient group and 68 ± 11 mmHg in the nondefi cient group (p = 0.07) One patient in the nondefi cient group and 1 patient in the defi cient group had severe hypercapnia defi ned by a PaCO 2 level of more than 55 mmHg. Severe pulmonary hypertension (systolic pulmonary artery pressure > 55 mmHg) was observed in 1 patient with α 1 -AT defi ciency and in none of the patients without defi ciency. Sixteen patients in the defi cient group and 12 patients in the nondefi cient group had oxygen supplementation at rest. Out of the 17 patients with α 1 -AT defi ciency, the PI phenotype was available in 15. All of them had PIZZ phenotype.
Upon CT scan examination, all patients had heterogeneously distributed emphysema, which predominated on the
Nondefi cient group
In the nondefi cient group, RV, TLC, FRC, FEV 1 , 6MWD, dyspnea score, and PaO 2 values improved signifi cantly at 3-6 months compared with baseline, the gain being persistent at 1 year.
Comparison between the two groups
At 3-6 months, the FEV 1 values were not signifi cantly different but a statistical difference was observed at 1 year (26 ± 9% and 40 ± 17% pred, in the defi cient group and the nondefi cient group respectively; p < 0.005). Compared with pre-operative mean value, the relative gain in FEV 1 at 3-6 months was 29 ± 26% and 34 ± 36% pred in the defi cient and in the nondefi cient group, respectively (p = NS). The relative gain in FEV 1 at 1 year compared with baseline tended to be higher in the nondefi cient group than in the defi cient group (34 ± 35% and 16 ± 24%, respectively, without reaching statistical signifi cance; p = 0.07).
The proportion of patients with improvement in FEV 1 and 6MWD in the two groups is given in Table 3 . Although no statistical signifi cance was achieved, the percentage of patients improved at 1 year tended to be higher in the nondefi cient group. of emphysema, since better functional results have been observed after upper lobe surgery McKenna et al 1997; Ingenito et al 1998; Coxson et al 2003; NETT 2003) . As a matter of fact, the predominant site of destruction was in the lower lobes in all of our patients but only in 10/21 patients in the study by Tutic et al (2004) . Another fi nding of our study was the difference found in α 1 -AT defi cient patients between objective improvement (lung volume measurements, 6MWD, PaO 2 ) and subjective benefi t (dyspnea score) which persisted for 1 year. Such a difference had been previously reported in nondefi cient patients (Gelb et al 1998 (Gelb et al , 2001 Flaherty et al 2001) and was also found by Tutic et al (2004) . By contrast with previous studies, our study analyzed the results of unilateral LVRS in defi cient patients. Our surgical approach (unilateral thoracotomy) could not explain the poorer results of LVRS in α 1 -AT defi cient patients. Indeed, the nondefi cient patients had the same surgical approach, giving results in accordance with those previously reported after unilateral LVRS (relative gain in FEV 1 of 20%-30% in most studies) (Flaherty and Martinez 2000) . α 1 -AT defi cient patients are known to have emphysematous lesions which predominate on lower lobes, and, as said previously, poorer 6-month results have been observed when LVRS is performed on lower lobes rather than on upper lobes McKenna et al 1997; NETT 2003; Ingenito et al 1998; Coxson et al 2003) . Thus, a question arises: are the functional results in defi cient patients related to the location of emphysematous lesions or to the α 1 -AT defi ciency per se? In our series, all defi cient patients had predominant lowerlobe lesions whereas one third of nondefi cient patients had predominant lower-lobe lesions. The results of LVRS in our nondefi cient patients with predominant lower-lobe lesions showed that, as was the case in defi cient patients, FEV 1 returned to baseline at 1 year (data not shown). Therefore, we hypothesize that the poorer functional results in defi cient patients might be related to nonapical emphysema surgery rather than to α 1 -AT defi ciency.
Whether α 1 -AT defi cient patients who present with severe emphysema are suitable for LVRS or for lung transplantation remains open to debate. The functional results of lung transplantation are clearly superior to what is provided by LVRS (Gelb et al 1998) but the risks of the procedure are much higher for lung transplantation. The current policy at our center is to explain the potential risks and benefi ts of both procedures in patients with emphysema and to favour LVRS when the selection criteria are met. In the particular case of α 1 -AT defi cient patients, given our results, we tend to Discussion α 1 -AT defi ciency is an hereditary disorder characterized by low serum levels of α 1 -AT and increased risk of emphysema at an early age. Augmentation therapy by regular intravenous infusion of α 1 -AT has been shown to increase the serum level of this protein and is recommended for the management of α 1 -AT defi cient patients, particularly in individuals with moderate airfl ow obstruction (ATS-ERS 2003) . A clinical effi cacy in terms of survival or pulmonary function has been suggested but has never been convincingly demonstrated (Seersholm et al 1997; AADR 1998; Wencker et al 2001) . Besides augmentation therapy, 2 surgical procedures may be considered in case of advanced emphysema: lung transplantation and LVRS.
In their study describing the results of 150 patients who underwent LVRS, Cooper et al (1996) stated that the benefi t was less important in patients with lower lobe lesions or α 1 -AT defi ciency. The functional results of LVRS in defi cient patients have been previously analyzed in a more specifi c way by several authors (Cassina et al 1998; Gelb et al 1999; Ritscher et al 1999) . Cassina et al (1998) noted a transient functional improvement in patients with α 1 -AT defi ciency with return to baseline 6-12 months after surgery except for 6MWD. In contrast, Gelb et al (1999) , reporting the results of LVRS in 6 α 1 -AT defi cient patients, observed a modest improvement in some functional parameters lasting more than 22 months post-operative in 4 cases. Similarly, no important differences were observed 18 months after surgery between 8 α 1 -AT defi cient patients and 46 patients without defi ciency (Ritscher et al 1999) . Recently, Tutic et al (2004) reported results of LVRS in 21 α 1 -AT defi cient patients. A functional benefi t in terms of FEV 1 persisted up to 1 year after surgery but the gain of LVRS was smaller and shorter lasting than in patients with pure smoker's emphysema. In the above-mentioned studies, baseline status of the patients was similar to that of our patients, but the surgical approach was always bilateral.
The results of the present study show that the effects of LVRS in α 1 -AT defi cient patients are short lasting since most functional parameters returned towards baseline at 1 year after surgery. The magnitude of the gain in FEV 1 , walking distance, and dyspnea score in the defi cient group was not lower than in nondefi cient patients but the duration of improvement was shorter. Thus, our results are in accordance with those of Cassina et al (1998) but are not in opposition to those of Tutic et al (2004) . In the latter study, the duration of improvement was somewhat longer but the difference might be explained by the distribution favour lung transplantation but the LVRS remains an option even though the duration of benefi t is probably shorter than in nondefi cient patients.
In summary, our experience suggests that the functional benefi t is short lasting in α 1 -AT defi cient patients who undergo unilateral LVRS for emphysema. Based on these results, we consider that LVRS remains an option but that lung transplantation, if possible, is more appropriate for most of these patients.
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